Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML

被引：0
|
作者：
Kang, Dongwoo [1 ]
Passarell, Julie [2 ]
Abutarif, Malaz A. [1 ]
Mendell, Jeanne [1 ]
Yin, Ophelia [1 ]
机构：
[1] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[2] Cognigen Corp, Buffalo, NY USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122582
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] CPX-351 Exposure-Response Analyses for Efficacy and Safety in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Wang, Qi
    Gosselin, Nathalie H.
    Absalon, Michael J.
    Kolb, E. Anders
    Marier, J. F.
    Alonzo, Todd A.
    Faderl, Stefan
    Cooper, Todd M.
    BLOOD, 2020, 136
  • [2] Concentration-QT Analysis of Quizartinib in Patients with Relapsed/Refractory AML
    Kang, Dongwoo
    Lin, Kuan-ju
    Ludwig, Elizabeth
    Yin, Ophelia
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S23 - S24
  • [3] Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
    Connarn, Jamie N.
    Witjes, Han
    van Zutphen-van Geffen, Marielle
    de Greef, Rik
    Campbell, Timothy B.
    Hege, Kristen
    Zhou, Simon
    Lamba, Manisha
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (11): : 1687 - 1697
  • [4] Azacitidine in Relapsed and Refractory AML: Efficacy for Patients Relapsing As MDS Post AML
    Ivanoff, Sarah
    Lemasle, Emilie
    Gruson, Berengere
    Merlusca, Lavinia
    Charbonnier, Amandine
    Parcelier, Anne
    Damaj, Gandhi
    Royer, Bruno
    Marolleau, Jean Pierre
    BLOOD, 2012, 120 (21)
  • [5] Exposure-Response of Entospletinib (ENTO) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
    Gupta, Sneha
    Meng, Amy
    Sharma, Shringi
    Ye, Wei
    Silverman, Jeffrey
    Abella, Esteban M.
    Mathias, Anita
    BLOOD, 2017, 130
  • [6] Exposure-Response Analyses of Various Efficacy and Safety Endpoints in Support of Registrational Dose Selection of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma
    Milberg, Oleg
    Chiu, Joannellyn
    Hazra, Anasuya
    Upadhyay, Sameer
    Kroog, Glenn S.
    Lorenc, Karen Rodriguez
    Davis, John D.
    Dicioccio, A. Thomas
    Harnisch, Lutz O.
    Chittenden, Jason
    BLOOD, 2024, 144 : 7056 - 7057
  • [7] Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Zhu, Min
    Kratzer, Andrea
    Johnson, Jessica
    Holland, Chris
    Brandl, Christian
    Singh, Indrajeet
    Wolf, Andreas
    Doshi, Sameer
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (02): : 168 - 179
  • [8] Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
    Mehrotra, Shailly
    Gopalakrishnan, Mathangi
    Gobburu, Jogarao
    Ji, Jiuping
    Greer, Jacqueline M.
    Piekarz, Richard
    Karp, Judith E.
    Pratz, Keith W.
    Rudek, Michelle A.
    CLINICAL CANCER RESEARCH, 2017, 23 (21) : 6421 - 6429
  • [9] Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma
    Ferron-Brady, Geraldine
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Visser, Sandra
    Jewell, Roxanne C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1282 - 1292
  • [10] Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Cortes, Jorge E.
    Ganguly, Siddhartha
    Kraemer, Alwin
    Levis, Mark J.
    Martinelli, Giovanni
    Perl, Alexander E.
    Russell, Nigel H.
    Choi, Youngsook
    Mendell, Jeanne
    Namuyinga, Ruth
    Hoang Pham
    Said, Nabil
    Wang, Yibin
    Mitov, Tsvetomir
    Kim, Ben
    Khaled, Samer K.
    BLOOD, 2019, 134
12345